Meeder Asset Management Inc. Sells 42,497 Shares of Zoetis Inc. $ZTS

Meeder Asset Management Inc. lessened its stake in Zoetis Inc. (NYSE:ZTS) by 93.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,789 shares of the company’s stock after selling 42,497 shares during the quarter. Meeder Asset Management Inc.’s holdings in Zoetis were worth $200,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the company. RFG Advisory LLC raised its stake in shares of Zoetis by 4.9% in the fourth quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock valued at $215,000 after buying an additional 80 shares during the period. Quest 10 Wealth Builders Inc. grew its stake in shares of Zoetis by 4.7% during the 4th quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company’s stock worth $240,000 after acquiring an additional 86 shares during the period. Financial Engines Advisors L.L.C. grew its stake in shares of Zoetis by 4.4% during the 3rd quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company’s stock worth $299,000 after acquiring an additional 87 shares during the period. Physician Wealth Advisors Inc. increased its holdings in Zoetis by 17.4% in the 1st quarter. Physician Wealth Advisors Inc. now owns 615 shares of the company’s stock worth $73,000 after acquiring an additional 91 shares during the last quarter. Finally, Smithfield Trust Co raised its stake in Zoetis by 4.2% in the 4th quarter. Smithfield Trust Co now owns 2,294 shares of the company’s stock valued at $290,000 after acquiring an additional 92 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on ZTS shares. BNP Paribas Exane cut their target price on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating for the company in a research report on Tuesday, August 11th. Wall Street Zen cut shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Piper Sandler cut their price objective on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a report on Monday, August 10th. Zacks Research lowered shares of Zoetis from a “hold” rating to a “strong sell” rating in a research note on Monday, August 10th. Finally, Weiss Ratings downgraded Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, June 12th. Eight analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $109.62.

Zoetis Stock Performance

Zoetis stock opened at $76.78 on Thursday. Zoetis Inc. has a 1-year low of $71.00 and a 1-year high of $160.48. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The firm has a market capitalization of $31.73 billion, a PE ratio of 12.65, a price-to-earnings-growth ratio of 1.73 and a beta of 0.74. The firm’s 50 day simple moving average is $75.92 and its 200 day simple moving average is $97.81.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, topping the consensus estimate of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The firm had revenue of $2.47 billion for the quarter, compared to analysts’ expectations of $2.50 billion. During the same quarter in the prior year, the firm posted $1.76 earnings per share. The business’s quarterly revenue was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, analysts expect that Zoetis Inc. will post 6.2 earnings per share for the current fiscal year.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.